Aug. 6, 2020: Recent trends in drug interaction rates; integrase inhibitors and cardiac event risk; a deep dive into HIV drug resistance in Florida; frailty symptoms and neurocognitive disorders amidst high CD4 counts.
An interview with Andrew Hill, Ph.D., about his research presented at AIDS 2020.
July 23, 2020: Depression and HIV risk mitigation among MSM; a consistent HIV provider is good for CD4 and viral load; spirituality and HIV prevention; HCV treatment access and reinfection risk.
July 16, 2020: Starting HIV treatment during hospitalization for people who use drugs; type of substance use affects viral suppression odds; benefits of a cross-disciplinary medical support team; does STI recency dictate PrEP necessity for women?
COVID-19 or no, there was still plenty to learn at this year's virtual conference, including for U.S. clinicians seeking to improve the care and treatment they provide to their patients living with HIV.
A pair of presentations at AIDS 2020 provides some of the largest studies to date on COVID-19 among people with HIV, but leaves us with many questions about the interplay between the two viruses.
July 9, 2020: Abysmal HIV testing rates in U.S. ambulatory care settings; STI testing frequency in PrEP users; trends in U.S. PrEP uptake; integrating opioid therapy with HCV care in people who inject drugs.
People living with HIV in the U.S. are experiencing increases in body mass index at a rate three times greater than that of the general U.S. population, according to new research presented at AIDS 2020.
July 1, 2020: Quantifying bone fracture risks; real-world lipid effects of switching to TAF; pulmonary function impairment in MSM; immunomodulatory drugs and viral load blips.
June 18, 2020: Existing evidence-based interventions aren't enough to close HIV's racial gap; transgender patient outcomes in the HIV care continuum; meeting long-term needs of formerly incarcerated people; acute respiratory illness severity and HIV status.